DALLAS, Texas—Yesterday Neurolens announced the completion of an additional $67 million in financing. The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wace, and existing investors including Bluestem Capital. The investment will fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens, according to an announcement from the company. “While we have grown tenfold in the past three years, the unmet patient need remains massive,” said Pierre Bertrand, Neurolens CEO.

“Nearly 6 out of 10 Americans are reporting daily symptoms of Digital Vision Syndrome (DVS), and we are excited to continue bringing solutions to independent optometry to meet their needs. We are grateful to see both current and new investors embrace our mission to transform eyecare beyond visual acuity.”
Dr. Eric Bednarski, a partner at MVM, commented, “Neurolens offers a remarkable solution to address the widespread problems that patients experience due to DVS. We are pleased to partner with Neurolens to support its continued growth.” Dr. Akhilesh Pathipati, partner at MVM, added, “The team at Neurolens has shown tremendous leadership and dedication while innovating in a market poised for growth. We are thrilled to work with them to continue changing the lives of patients.” Drs. Bednarski and Pathipati joined the Neurolens board of directors as a part of this financing.